With an EV/Sales ratio of 5.5x sales, I would say that the market is expecting Enzolytics to have sales of approximately $109 million. Enzolytics, Inc. has seen a significant increase in its total expenses from 2019. Enzolytics, Inc. Check it out on https://t.co/0LdCQCWC28. Enzolytics has funding in place and has the capital to move forward on all fronts. Plano, TX 75074 Microcapdaily has been reporting on ENZC since the day the merger was reported and the stock was sub $0.003. Source: Press Release. Onfolio Holdings introduction of the generative AI search function for MightyDeals.com has increased the companys stock price, reflecting the markets positive response to this innovative technology. IPF is a platform technology that can be used to facilitate a broad range of applications. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. The flagship compound of the company is named Immune Therapeutic Vaccine-1 (ITV-1) and represents a suspension of Inactivated Pepsin Fraction (IPF) that could be effective in the treatment of HIV/AIDS. However, numerous companies are already selling HIV Drugs. SNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm. In my view, investors have appreciated the new information. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. Chinese Nasdaq listings the next meme stock rally? In a very big move Enzolytics recently expanded its lab to the campus of Texas A&M University at its Institute for Preclinical Studies. Source: Press Release - Patent. Enzolytics: Enzolytics, Inc. Finalizing Regulatory Labeling Requirements for Delivery of ITV-1 Treatments for Use in Hospitals in Central and Eastern Africa - Company also Provides Additional Details on the Sale of Biogenysis and Virogentics Apr 17, 2023 BioSpace Plus, lockup expiry is tomorrow, so this is a blatant pump and dump: pic.twitter.com/QnYVoDnqqr, Adam Gefvert, CFA (@Shiningboy) May 26, 2023. ITV-1 has been shown to modulate the immune system. we will never share your email with anyone. Dr. Saggar is also an adjunct clinical associate professor at Touro College of Osteopathic Medicine in New York City. IPF is a platform technology that can be used to facilitate a broad range of applications. [http://www.bioclonetics.com/validation.html]. Shareholders need to understand well that they may have to wait many years until Enzolytics Inc. can report sales. Enzolytics has funding in place and has the capital to move forward on all fronts. As per usual, with gains of around 135%, you can probably guess that retail is all over it. However, there are no revenues and its Bulgarian partner denies that Enzolytics has a stake in it. - Reviewing and analyzing the system requirement. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech or any other person that the objectives and plans of Enzolytics will be achieved should not regard the forward-looking statements as a representation. Besides, the competition in the HIV drugs market is significant. With our main focus in spirochetal diseases, such as Lyme Disease and Leptospirosis, we . Microcapdaily first reported on ENZC on September 15 when the stock was still deep in triple zero land and moving up fast after the Company first reported the LOI to merge with BioClonetics. He is board-certified in Internal Medicine and Infectious Disease and is a Fellow of the Infectious Disease Society of America. Enzolytics Inc (OTCMKTS: ENZC) is making a dynamic run up the charts emerging as a volume leader in small caps and one of the most exciting stories on the exchange that has attracted legions of new shareholders as it continues northbound with power. The company says the study was carried out by Petia Genova-Kalou. In addition, the company will most likely need financing for the construction of its laboratory in Europe. As part of the deal, TScan will get an upfront payment of $30 million from Amgen and could earn more than $500 million if the collaboration is successful. $TCRX guess they're not done screwing with people yet. To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. He also serves as President & Chief Scientific Officer at Immunotech Laboratories, Inc. Reunion Neuroscience Inc.s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions, Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells, Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership, Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI, Wearable Devices Ltd. (NASDAQ: WLDS) Breaking Boundaries with AI, Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment, Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) Secure Partnership, ContraFect Corp (NASDAQ: CFRX): A Low Float Runner, Magoceuticals Inc. (NASDAQ: MGRX) Climbing Up The Charts, Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval, GSI Technology, Inc. (NASDAQ: GSIT): Pure AI Play Transforming Semiconductor Memory Solutions for Efficient AI Processing. Phone: (972)292-9414 Disclosure: We have not been compensated for this article/video. Adamis Pharmaceuticals, San Diego, CA, March 2017-Present, Chief Medical Officer. He completed his internal medicine residency and fellowship in infectious diseases at Saint Michael's Medical Center in Newark, New Jersey. $TCRX #TCRX nice wake up call watch the break above 5.47 to potential 6.25 test pic.twitter.com/FvoAYEFslG, APFK_ASIAN PICASSO. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. The current market capitalization is larger than $600 million. More than 400 articles written by the creators of Immunocal. PLANO, TX/ ACCESSWIRE/ April 16, 2020/ Enzolytics- is pleased to update shareholders on the current corporate initiatives. BioClonetics Immunotherapeutics, Inc. is a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Enzolytics' flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. Monitoring the companys financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better. I have no business relationship with any company whose stock is mentioned in this article. Harry H. Zhabilov has served as Chairman, President & Chief Science Officer at Immunotech Laboratories, Inc., Chairman, President & Chief Executive Officer for Enzolytics, Inc. and Treasurer . Amgen will have the rights to develop and sell any new drugs from this partnership. Responsible for defining, implementing and managing . Taking into account this fact, the announcement is positive: Enzolytics, Inc. today, announced it has accepted a proposal from a Houston based PCAOB Audit firm to Audit the Company's year-end financial statements, subject to the receipt and acceptance of the engagement letter. Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics has a valuation of $982.1 million but I dont think the business is worth much in its current state. Enzolytics claims that these mAbs could be used to produce therapeutics treatments for various infectious diseases, including COVID-19. First, its possible that Im wrong about the. If the company raises capital, it will be able to easily pay its debts: Enzolytics, Inc. has delivered several announcements which may explain the most recent reaction in the stock price. Further our development in North America of our Flagship HIV immune treatment compound IPF. Immunotech is committed to creating drugs for the better health of mankind. I think Enzolytics is a sell and investors can take advantage of this by shorting the shares. These shares were issued on December 7, 2020. Prior to co-founding BioCLonetics, Mr. Cotropia served as a partner and senior counsel at Sidley Austin LLP. BioClonetics is in the final stage of development of a parent monoclonal antibody ("mAbs") (designated as Clone 3), which is non-toxic and has shown in initial in vitro testing to be effective against more than 95% of all strains and viral subtypes of HIV-1 against which it has been tested. Mr. Zhabilov is Chief Scientific Officer of Enzolytics, Inc. Endava. Moreover, the Company has proprietary methodology needed to produce anti-coronavirus monoclonal antibodies targeting such sites. Interestingly, some traders are surprised it managed to trade such massive volumes early intraday. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. The competition in the market is significant. Founded in 2004, Enzolytics, Inc. owns licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS. He has clinical experience as a staff physician at the University of Pennsylvania, has worked in cell biology at the Center for Biologics Evaluation and Research Division at the Food and Drug Administration in Bethesda, Maryland, and has further clinical experience as a physician at the University of Texas Health Center. Immunotech Laboratories BG. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. $ONFO "AI program" is laughable. See our first report on Enzolytics here when ENCZ was sub $0.003. During his legal career, Mr. Cotropia represented clients in the diverse areas of biotech, aerospace, electronics, the Internet, commercial products, and oil and gas equipment and processes. The company has issued a significant amount of shares in the last five years. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. This compound is being developed to address the treatment of anxiety disorders. It is also very beneficial that Enzolytics, Inc. received $1.2 million in new financing: Enzolytics, Inc. today, announced it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for "Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor - Pharmaceutical Composition for Treatment" and has received the third tranche of the $1.2 million dollar financing. If you have an ad-blocker enabled you may be blocked from proceeding. Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. Joseph Tucker, Ph.D., Enverics director and CEO, underlined the significance of the USPTOs favorable decision concerning their lead candidate, EB-373. Anderson Cancer Center and the Food and Drug Administration Center, and the Food and Drug Administration Center for Biologics Evaluation and Research (CBER) where he had hands-on experience with immunotherapeutic biotechnology platforms directly related to monoclonal antibodies. and it looks like the drugs are in an early phase of development, so I doubt this business should be worth much at the current time. While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings financial performance is crucial. According to CEO Charles S. Cotropia: We are actively moving forward in our production and testing of such antibodies. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know whats going on with ENZC. Such application to the NSF and a corresponding application to the NIH are now pending. 9,000,000 servings sold per month. today announced a multi-year collaboration that will use TScans proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohns disease.